Jared Gollob's most recent trade in Kymera Therapeutics Inc was a trade of 35,300 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 35,300 | 35,300 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 17,650 | 127,642 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 89.66 per share. | 02 Mar 2026 | 3,048 | 122,029 | - | 89.7 | 273,276 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.04 per share. | 02 Mar 2026 | 2,519 | 119,018 | - | 85.0 | 214,207 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 87.75 per share. | 02 Mar 2026 | 1,510 | 126,132 | - | 87.8 | 132,504 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.78 per share. | 02 Mar 2026 | 1,437 | 117,581 | - | 85.8 | 123,267 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 88.50 per share. | 02 Mar 2026 | 1,055 | 125,077 | - | 88.5 | 93,368 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 84.00 per share. | 02 Mar 2026 | 492 | 121,537 | - | 84.0 | 41,326 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 86.62 per share. | 02 Mar 2026 | 447 | 117,134 | - | 86.6 | 38,721 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.33 per share. | 08 Dec 2025 | 49,307 | 159,299 | - | 5.3 | 262,806 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 49,307 | 34,083 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 88.02 per share. | 08 Dec 2025 | 18,357 | 127,183 | - | 88.0 | 1,615,811 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 87.37 per share. | 08 Dec 2025 | 13,759 | 145,540 | - | 87.4 | 1,202,139 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 90.12 per share. | 08 Dec 2025 | 8,562 | 114,692 | - | 90.1 | 771,630 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 89.43 per share. | 08 Dec 2025 | 3,929 | 123,254 | - | 89.4 | 351,356 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 91.46 per share. | 08 Dec 2025 | 3,300 | 111,392 | - | 91.5 | 301,831 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 92.19 per share. | 08 Dec 2025 | 1,400 | 109,992 | - | 92.2 | 129,066 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.37 per share. | 15 Oct 2025 | 29,264 | 140,304 | - | 60.4 | 1,766,668 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.31 per share. | 15 Oct 2025 | 28,999 | 147,358 | - | 1.3 | 37,989 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 28,999 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 22,210 | 0 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 15 Oct 2025 | 22,210 | 169,568 | - | 2.1 | 46,197 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 62.72 per share. | 15 Oct 2025 | 14,896 | 116,445 | - | 62.7 | 934,326 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 61.49 per share. | 15 Oct 2025 | 8,963 | 131,341 | - | 61.5 | 551,161 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 63.09 per share. | 15 Oct 2025 | 6,453 | 109,992 | - | 63.1 | 407,099 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 13 Oct 2025 | 3,114 | 118,359 | - | 60 | 186,840 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.31 per share. | 13 Oct 2025 | 800 | 120,800 | - | 1.3 | 1,048 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2025 | 800 | 28,999 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 13 Oct 2025 | 673 | 121,473 | - | 2.1 | 1,400 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2025 | 673 | 22,210 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 30,000 | 125,740 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.33 per share. | 03 Mar 2025 | 4,695 | 121,045 | - | 30.3 | 142,386 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 03 Mar 2025 | 1,045 | 120,000 | - | 31.0 | 32,400 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 15 Jul 2024 | 23,145 | 118,885 | - | 2.1 | 48,142 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 23,145 | 22,883 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.15 per share. | 15 Jul 2024 | 16,455 | 95,740 | - | 45.1 | 742,925 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 15 Jul 2024 | 16,455 | 112,195 | - | 2.1 | 34,226 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 16,455 | 46,028 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.59 per share. | 15 Jul 2024 | 13,281 | 105,604 | - | 45.6 | 605,522 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 46.10 per share. | 15 Jul 2024 | 9,864 | 95,470 | - | 46.1 | 454,696 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 146,250 | 146,250 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 24,375 | 99,084 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 41.41 per share. | 01 Mar 2024 | 2,022 | 97,062 | - | 41.4 | 83,738 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 42.39 per share. | 01 Mar 2024 | 1,106 | 95,956 | - | 42.4 | 46,886 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.25 per share. | 01 Mar 2024 | 216 | 95,740 | - | 43.3 | 9,343 | Common Stock |
| Kymera Therapeutics Inc | Gollob Jared | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 27 Feb 2024 | 400 | 74,709 | - | 45 | 18,000 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 400 | 62,483 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 27 Feb 2024 | 400 | 75,109 | - | 2.1 | 832 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 46,137 | 62,883 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Gollob Jared | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 09 Feb 2024 | 46,137 | 120,846 | - | 2.1 | 95,965 | Common Stock |
| Kymera Therapeutics Inc | Gollob Jared | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.39 per share. | 09 Feb 2024 | 38,739 | 82,107 | - | 35.4 | 1,371,058 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.09 per share. | 09 Feb 2024 | 7,398 | 74,709 | - | 36.1 | 267,013 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 18,750 | 76,007 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.88 per share. | 01 Mar 2023 | 1,001 | 75,006 | - | 30.9 | 30,908 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 01 Mar 2023 | 297 | 74,709 | - | 31.4 | 9,325 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 10,208 | 29,799 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.31 per share. | 04 May 2022 | 10,208 | 47,465 | - | 1.3 | 13,372 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 9,792 | 109,020 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 04 May 2022 | 9,792 | 57,257 | - | 2.1 | 20,367 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 75,800 | 75,800 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 12,600 | 37,257 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.31 per share. | 01 Nov 2021 | 20,000 | 62,547 | - | 1.3 | 26,200 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 20,000 | 40,007 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 62.34 per share. | 01 Nov 2021 | 15,911 | 28,722 | - | 62.3 | 991,946 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 61.50 per share. | 01 Nov 2021 | 15,134 | 44,633 | - | 61.5 | 930,709 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 01 Nov 2021 | 14,996 | 39,653 | - | 2.1 | 31,192 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 14,996 | 118,812 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 62.89 per share. | 01 Nov 2021 | 8,514 | 31,139 | - | 62.9 | 535,442 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.40 per share. | 01 Nov 2021 | 7,387 | 59,767 | - | 60.4 | 446,142 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 63.50 per share. | 01 Nov 2021 | 5,280 | 25,859 | - | 63.5 | 335,287 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 01 Nov 2021 | 4,607 | 67,154 | - | 2.1 | 9,583 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 4,607 | 133,808 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 63.17 per share. | 01 Nov 2021 | 4,065 | 24,657 | - | 63.2 | 256,799 | Common Stock |
| Kymera Therapeutics Inc | Jared Gollob | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 64.34 per share. | 01 Nov 2021 | 1,202 | 24,657 | - | 64.3 | 77,333 | Common Stock |